Pharsight

Zerviate generic

Zerviate is an ophthalmic drug owned by Eyevance. It contains the active ingredient cetirizine hydrochloride. Zerviate was first authorized for market use on 30 May 2017, and is available in solution and drops dosage forms.

When will Zerviate generic be available?

The generics of Zerviate are expected to be released after 09 January, 2033. This release date is because of the expiry of the last patent (US9254286*PED) covering Zerviate.

Zerviate uses

Zerviate is primarily used for the treatment of ocular itching associated with allergic conjunctivitis. The active ingredient, cetirizine hydrochloride, works by reducing the effects of a natural chemical histamine in the body that can lead to symptoms such as itching.

Zerviate patent expiration

Zerviate has a total of 6 patents, none of which have expired. The last patent is set to expire on 09 January, 2033. This means that the Zerviate generic might not be available until then. Below are the details of the patent:

Zerviate dosage

Want to ask something?